Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
CNS Neurol Disord Drug Targets. 2020 May 17;:
Authors: Xiaowei Z, Yuanbo L
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare invasive extranodal non-Hodgkin lymphoma, the vast majority of which is diffuse large B-cell lymphoma (DLBCL). Although high-dose methotrexate-based immunochemotherapy achieves a high remission rate, the risk of relapse and related death remains a crucial obstruction to long-term survival. Novel agents for the treatment of lymphatic malignancies have greatly broadened the horizons of therapeutic options for PCNSL. The PI3K/AKT/mTOR signaling pathway is one of the most important pathways for B-cell malignancy growth and survival. Novel therapies that target key components of this pathway have shown antitumor effects in many B-cell malignancies, including DLBCL. This review will discuss the aberrant status of the PI3K/AKT/mTOR signaling pathways in PCNSL and the application prospects of inhibitors in hopes of providing alternative clinical therapy strategies and improving prognosis.
PMID: 32416683 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Xiaowei Z, Yuanbo L Tags: CNS Neurol Disord Drug Targets Source Type: research
More News: Brain | Cancer & Oncology | Drugs & Pharmacology | Lymphoma | Methotrexate | Neurology | Non-Hodgkin's Lymphoma | Primary CNS Lymphoma